https://mindmedicinelaw.com/briefing/pharmacist-training-for-psychedelic-medicine-u-s-readiness-grows-20261013-49829The Psychedelic Journalen2026-10-13T22:04:01.630882+00:00Pharmacist Training for Psychedelic Medicine: U.S. Readiness Growspharmacist training, psychedelic medicine, mdma, psilocybin, fda approval, pharmacy education, controlled substances, public health, regulatory readiness, patient safetyhttps://mindmedicinelaw.com/briefing/psychedelic-medicine-after-fda-approval-us-policy-and-market-readiness-20261013-49653The Psychedelic Journalen2026-10-13T15:06:13.305711+00:00Psychedelic Medicine After FDA Approval: US Policy and Market Readinesspsychedelic medicine, fda approval, us policy, dea scheduling, vicente llp, clinical operations, investor considerations, state law, remediation strategies, risk managementhttps://mindmedicinelaw.com/briefing/oregon-s-psilocybin-safety-audit-regulatory-success-cost-barriers-remain-20261013-49654The Psychedelic Journalen2026-10-13T15:05:58.965101+00:00Oregon’s Psilocybin Safety Audit: Regulatory Success, Cost Barriers Remainoregon psilocybin law, psilocybin safety audit, psychedelic regulation, access barriers, public health policy, measure 109, equity in psychedelics, psychedelic industry costs, facilitator training, regulatory compliancehttps://mindmedicinelaw.com/briefing/oregon-s-psilocybin-centers-safety-standards-outpace-affordability-20261012-49478The Psychedelic Journalen2026-10-12T22:04:04.211481+00:00Oregon’s Psilocybin Centers: Safety Standards Outpace Affordabilityoregon psilocybin, psychedelic regulation, safety protocols, access barriers, public health policy, session cost, equity in psychedelics, oregon health authority, facilitator training, regulated psychedelicshttps://mindmedicinelaw.com/briefing/ai-s-expanding-role-in-preclinical-drug-development-implications-for-psychedelic-20261011-49589The Psychedelic Journalen2026-10-13T15:06:45.573805+00:00AI’s Expanding Role in Preclinical Drug Development: Implications for Psychedelic Researchai in drug discovery, preclinical development, psychedelic compounds, generative models, toxicity prediction, regulatory guidance, experimental validation, closed-loop optimization, fda policy, medicinal chemistryhttps://mindmedicinelaw.com/briefing/bdnf-biomarkers-and-ptsd-implications-for-psychedelic-trials-20261011-49570The Psychedelic Journalen2026-10-13T15:06:29.748282+00:00BDNF Biomarkers and PTSD: Implications for Psychedelic Trialsbdnf, ptsd biomarkers, psychedelic clinical trials, neuroplasticity, epigenetics, precision psychiatry, regulatory science, biomarker panel, personalized therapyhttps://mindmedicinelaw.com/briefing/living-meta-analysis-and-open-data-on-mdma-therapy-for-ptsd-20261011-49193The Psychedelic Journalen2026-10-12T15:04:18.844299+00:00Living Meta-Analysis and Open Data on MDMA Therapy for PTSDmdma-assisted therapy, ptsd, systematic review, meta-analysis, open data, randomized controlled trials, maps, evidence certainty, regulatory policy, psychedelic researchhttps://mindmedicinelaw.com/briefing/qualitative-insights-on-acute-inhaled-dmt-in-brazilian-clinics-20261007-49600The Psychedelic Journalen2026-10-13T15:06:58.990485+00:00Qualitative Insights on Acute Inhaled DMT in Brazilian Clinicsdmt, brazil, psychedelic research, qualitative study, clinical trials, subjective experience, regulatory context, ayahuasca, risk management, cultural factors